TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety of Fecal Microbial Transplantation with immunotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary MAC severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Subjects With at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Partial Onset Seizure (Type I) Frequency Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinician-Administered PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: language performance on object and action naming tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurophysiological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Surufatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lipidemic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of estimated GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: onset of microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum tolerated dose (MTD) of cabozantinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to composite all-cause allograft loss or irreversible loss of allograft function
Endpoint domain: Mortality/survival
Primary endpoint: Area under the curve of plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with Intraocular Inflammation (IOI) Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Algorithm AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of CAR-T cell immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate of dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of patients with Prostate Specific Antigen (PSA) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of folate acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Distribution Volume of 11C-ER176
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Citrated Functional Fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Control of hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Responders at 3-months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total seroma aspirate volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (ORR) based on Evaluation Criteria In Solid Tumors (RECIST) 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall response rate (ORR) based on Lugano criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Six-month progression free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Calcium (albumin-corrected) serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miRNA profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLE Responder Index (SRI) Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of ADP-induced platelet aggregation at 90 min after meals consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical or microbiologically proven paratyphoid infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of ZIKV persistence in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Language
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adaptive/development skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinically Significant Safety Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced HIV-related risk sexual behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Safety of TCR-T treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Jackson Total Symptom Score (JTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of endoscopic sessions to achieve resolution of stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of successful treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score after treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than a Prespecified Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline to Day 11 in SARS-CoV-2 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnostic accuracy of Virtual Touch Tissue Imaging Quantification (VTIQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response to medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral immunity by seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With at Least 50% Reduction From Baseline of Monthly Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of expired oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the curve of YM060 plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal concentration of YM060 plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Remission with Incomplete Count Recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes of the plasma concentrations of Activins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes of the plasma concentrations of Follistatins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Death or secondary valve replacement
Endpoint domain: Mortality/survival
Primary endpoint: Attendance rates to the KAPA intervention sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the KAPA intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expression of progesterone receptors and apoptotic factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diffusion and Myelin Fraction Water Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post and core survival
Endpoint domain: Mortality/survival
Primary endpoint: Airway oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed a Semi-Structure Interview
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of the combination treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Minutes of Moderate-to-Vigorous Physical Activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate to home monitoring prompts
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Binge Eating Sum Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weekly Average Binge-eating Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Reported Reward Sensitivity Subscale Score During Estradiol Manipulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline on the MacArthur-Bates Communication Development Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in communication during parent-child and clinician-child interactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on the Social Responsiveness Scale (SRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on the Clinical Global Impression Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Sexual Risk Behavior for HIV Acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pocket depth (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical attachment level (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plaque index (0-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects That Withdrew Due to a Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge of Care Options (KOCO)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medical Communication Competence Scale (MCCS)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Engagement in Cancer Self-Management Activities Scale (ECSMAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximal knee extensor speed and power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Seroresponse after MenACWY-CRM vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Ranked Gravimetric Sweat Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to dementia
Endpoint domain: Mortality/survival
Primary endpoint: Longest Duration of Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Delay of second medical opinion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of fistula thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vaginal fluid Covid-19 PCR test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of red blood cell packs transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Shannon Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency and severity of toxicity associated with post-transplant aldesleukin therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Range of Motion of lumbar spine side flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School Grades
Endpoint domain: Life impact
Endpoint subdomain: Academic problems
Primary endpoint: Behavior Problems in School
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence rate of urosepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of diabetic ketoacidosis (DKA)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of lower extremity amputation
Endpoint domain: Adverse events/effects
Primary endpoint: number of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement of IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Agreement of Corneal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Opioid consumption in milligram morphine equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Population coverage of HPV vaccination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the concentration-time curve over the dosing interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission to the ICU
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 12-lead Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Body Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Total Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline for Numerical Rating Scale (NRS) Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss >5% of baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pancreatic uptake of radiolabeled Exendin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage Time Spent Above Glucose Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospital Length-of-stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of ophthalmic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Pupil Constriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-illumination pupil response (PIPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Toxicity of Single-dose Y2B8 Radioimmunotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Who Are Progression-free
Endpoint domain: Mortality/survival
Primary endpoint: Serum prealbumin and albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical skills score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Symptoms Scale Score of ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to goal feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Sugar level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Total MADRS Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Continuous Performance Task Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Irritability Subscale of the Aberrant Behavior Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients no longer dependent on immunosuppressive drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Change in Low Density Lipoprotein (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in occurrences of binge eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in occurrences of compensatory weight control behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychosocial impairment due to eating disorder symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Jefferson Empathy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in New Freezing of Gait Questionnaire - NFOG-Q
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the expression of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tear Break-Up Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ocular Staining Score (OSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Schirmer Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Cigarettes Smoked Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PE/DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: State Entropy Index (SE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of 11C-acetate PET/CT Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of the metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Obstructive Sleep Apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post operative VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained undetectable serum HCVRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of fallers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Upper-extremity Fugl-Meyer Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in absolute neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Adrenal Insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time Required for Recovery From Adrenal Suppression to Normal Adrenal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: extended Glasgow Outcome Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Anti-5T4 antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8+ve cellular response to 5T4 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma concentrations of DRV and RTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in upper GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in NTproBNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EuroQol 5 Dimensions, 3 Levels (EQ5D-3L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants That Experienced Drug Related Grade 3-4 AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants That Experienced Drug Related Grade 3-4 SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver
Endpoint domain: Adverse events/effects
Primary endpoint: Undetectable Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Adherence Rate - 7 Day
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication Adherence - 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum Endotoxin (LPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Area of Skin Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of myocardial perfusion abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe adverse events within 4 weeks after cell therapy
Endpoint domain: Adverse events/effects
Primary endpoint: relapse of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in antibiotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention